Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previous treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.
Original Article: Atezolizumab, Cobimetinib Combo Falls Short in Phase III mCRC Trial